ADDS Brain Function Testing Equipment

NegotiableUpdate on 05/06

Model

Nature of the Manufacturer: Producers

Product Category

Place of Origin

Online Consult

Overview

The ADDS brain function testing equipment uses a combination of graphic drawing parallel coordinate maps and radar maps to visualize and quantify EEG and behavioral control. Through real-time recording and point distribution calculation of the graphic drawing process, as well as variable scale singular value analysis and calculation of EEG physiological parameters in the time-frequency domain, it achieves the diagnosis and early risk assessment of Alzheimer's disease!

Product Details

ADDS Brain Function Testing EquipmentIt is a Class II medical device designed specifically for early identification of Alzheimer's disease (AD) and mild cognitive impairment. The device innovatively integrates internationally recognized cognitive scales and dynamic electroencephalography (EEG) monitoring technology. Through the dual dimensional evaluation of "subjective symptoms+objective physiology", it solves the industry pain points of strong subjectivity and low early identification rate in traditional screening, and provides fast, accurate, and standardized cognitive function screening and follow-up management tools for medical institutions at all levels, helping to achieve the clinical goal of "early detection, early diagnosis, and early intervention".

Core Technology: Precise Evaluation System for 3D Fusion

1. Dual dimensional data collection architecture

Scale evaluation layerIntegrating 17 international standard scales such as MMSE, MOCA, ADL, etc., guiding participants to complete 6 dimensions of tasks including memory, language, executive function, and visual spatial ability through touch based human-machine dialogue, synchronously recording behavioral data, covering core cognitive function assessment dimensions.

EEG monitoring layerUsing non-invasive brain computer interface technology, the dynamic changes of alpha waves, beta waves, and theta waves are collected in real-time through high-precision electrodes. Nonlinear feature parameters such as singular value decomposition matrix, complexity, approximate entropy, and wavelet entropy are extracted to capture early brain electrophysiological abnormalities of cognitive impairment and identify risks ahead of traditional methods.

2. AI intelligent analysis engine

Equipped with the variable scale maximum correlation minimum redundancy algorithm, the subjective data of the scale and the objective indicators of EEG are fused and modeled, effectively eliminating human evaluation bias. The clinical diagnosis is consistent and high, and the error rate is reduced by 60% compared to a single scale evaluation. The entire screening process can be completed in 10-15 minutes, and a quantitative evaluation report can be generated in real time, including cognitive domain scores, abnormal indicator labeling, risk level assessment, and personalized intervention recommendations.

Core advantage: Refactoring the efficiency and experience of cognitive screening

1. Breakthrough in objectivity and precision

Introducing EEG physiological indicators as the core evaluation basis, avoiding subjective interference such as relying on doctors' experience and patients concealing symptoms in traditional paper quality scales, with a coefficient of variation below 5%, providing reliable data support for early diagnosis, especially suitable for precise screening of mild cognitive impairment.

2. Full scene adaptation and convenient operation

Non invasive design, no need for blood draw or fasting, can be detected by wearing a lightweight EEG collector, with high acceptance among elderly patients;

Touch based human-computer interaction+one click start operation, real-time display of detection status on LED LCD screen, basic medical staff can get started after simple training;

Adapt to diverse scenarios such as hospitals, communities, and elderly care centers.

3. Closed loop management and scientific research empowerment

Support the establishment of patient records and long-term follow-up data tracking, which can form a "screening intervention rehabilitation" loop with ADTS memory impairment training system and ADMS cognitive neural regulation system. AI algorithms dynamically optimize rehabilitation plans based on EEG characteristics;

Data sampling rate, supporting multi-dimensional data storage, providing standardized datasets for academic research related to cognitive impairment.

4. High cost-effectiveness and localization advantages

As an original technology solution in China, the equipment procurement cost is lower than that of imported products, promoting the sinking of cognitive screening technology to counties and rural areas.

Scope of application: Covering the entire population and multiple scenarios

1. Core applicable population

Routine cognitive health screening for elderly people aged 60 and above;

Individuals with suspected symptoms such as memory loss, visual spatial impairment, decreased executive ability, and language barriers;

Monitoring of disease progression and evaluation of intervention effectiveness in patients with cognitive impairment;

Middle aged and elderly individuals who are concerned about their own brain health, as well as high-risk individuals with a family history of genetics.

2. Main application scenarios

Third class hospitals: neurology, geriatrics, psychiatry, clinical diagnosis and differential diagnosis;

Primary healthcare: large-scale population screening and risk stratification in community health service centers and township health centers;

Professional institutions: Mental health centers, rehabilitation hospitals, patient grading management and classification evaluation;

Health management: specialized assessment and health management services for cognitive health in physical examination centers and elderly care communities.

As the aging trend of China's population intensifies, the incidence rate of cognitive dysfunction increases year by year,ADDS Brain Function Testing EquipmentThe promotion and application of cognitive impairment screening can not only improve the coverage rate of early screening, but also delay the development of diseases through early intervention, significantly reduce the medical burden on families and society, provide standardized support for neuroscience research, and help achieve the prevention and treatment goals of elderly dementia in the "Healthy China 2030" planning outline.